Last kr123.80 DKK
Change Today +1.80 / 1.48%
Volume 164.3K
LUN On Other Exchanges
Symbol
Exchange
OTC US
Copenhagen
Stuttgart
OTC US
As of 11:01 AM 09/17/14 All times are local (Market data is delayed by at least 15 minutes).

h lundbeck a/s (LUN) Snapshot

Open
kr122.70
Previous Close
kr122.00
Day High
kr124.50
Day Low
kr121.90
52 Week High
03/24/14 - kr173.60
52 Week Low
10/9/13 - kr111.60
Market Cap
24.3B
Average Volume 10 Days
118.7K
EPS TTM
kr3.90
Shares Outstanding
196.4M
EX-Date
03/27/14
P/E TM
31.8x
Dividend
kr2.77
Dividend Yield
2.24%
Current Stock Chart for H LUNDBECK A/S (LUN)

Related News

No related news articles were found.

h lundbeck a/s (LUN) Details

H. Lundbeck A/S, a specialty pharmaceutical company, engages in the research, development, production, marketing, and sale of pharmaceuticals for the treatment of brain disorders in Europe, the United States, and internationally. The company’s principal products include Cipralex and Lexapro to treat depression, Ebixa for Alzheimer’s disease, Azilect to treat Parkinson’s disease, Xenazine for chorea associated with Huntington's disease, Sabril to treat epilepsy, Sycrest for bipolar disorder, and Onfi to treat Lennox-Gastaut syndrome. Its compounds in registration application include aripiprazole IM depot for the treatment of schizophrenia; Selincro for alcohol dependence; and Brintellix for the treatment of depression and anxiety. The company’s products in Phase III trials comprise IV carbamazepine for epilepsy; Brexpiprazole for psychiatric disorders; Desmoteplase for stroke; and Zicronapine for psychosis. Its products in Phase II trials include Tedatioxetine for depression and Lu AE58054 for Alzheimer's disease. H. Lundbeck A/S has strategic research collaboration with Ossianix, Inc. The company was founded in 1915 and is based in Valby, Denmark.

5,703 Employees
Last Reported Date: 08/7/14
Founded in 1915

h lundbeck a/s (LUN) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

h lundbeck a/s (LUN) Key Developments

H. Lundbeck A/S Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-08-2014

H. Lundbeck A/S Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-08-2014 . Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Palle Holm Olesen, Head of Investor Relations and Chief Specialist of Investor Relations.

H. Lundbeck A/S Presents at Bank of America Merrill Lynch Global Healthcare Conference, Sep-17-2014

H. Lundbeck A/S Presents at Bank of America Merrill Lynch Global Healthcare Conference, Sep-17-2014 . Venue: Bank of America Merrill Lynch Financial Centre, London, United Kingdom. Speakers: Palle Holm Olesen, Head of Investor Relations and Chief Specialist of Investor Relations.

H. Lundbeck A/S Announces Availability of Northera (Droxidopa) Capsules in the U.S

H. Lundbeck A/S announced that NORTHERATM (droxidopa) capsules for oral use are now available for healthcare providers to prescribe in the United States. NORTHERA, a norepinephrine prodrug, was recently approved by the U.S. Food and Drug Administration, and is now available across the United States through a specialty pharmacy. NORTHERA is approved for the treatment of orthostatic dizziness, lightheadedness, or the feeling that the patient is about to black out in adult patients with symptomatic neurogenic orthostatic hypotension (NOH) caused by primary autonomic failure (Parkinson's disease, multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy. Effectiveness beyond two weeks of treatment has not been demonstrated. The continued effectiveness of NORTHERA should be assessed periodically. NORTHERA is the only FDA-approved therapy for this condition and carries a boxed warning for supine hypertension. There are other serious risks associated with NORTHERA including hyperpyrexia and confusion, cardiovascular risk and allergic reactions. The most common adverse events in NORTHERA-treated patients in controlled clinical trials were headache, dizziness, nausea, and hypertension.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LUN:DC kr123.80 DKK +1.80

LUN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alkermes PLC $45.18 USD +0.73
Emergent Biosolutions Inc $22.17 USD -0.16
Lupin Ltd 1,365 INR +3.80
Nektar Therapeutics $13.72 USD +0.13
Salix Pharmaceuticals Ltd $159.89 USD +4.02
View Industry Companies
 

Industry Analysis

LUN

Industry Average

Valuation LUN Industry Range
Price/Earnings 29.7x
Price/Sales 1.6x
Price/Book 1.7x
Price/Cash Flow 29.7x
TEV/Sales 1.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact H LUNDBECK A/S, please visit www.lundbeck.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.